Share This Page
Drug Price Trends for NDC 51862-0886
✉ Email this page to a colleague
Average Pharmacy Cost for 51862-0886
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ERRIN 0.35 MG TABLET | 51862-0886-03 | 0.08490 | EACH | 2025-12-17 |
| ERRIN 0.35 MG TABLET | 51862-0886-01 | 0.08490 | EACH | 2025-12-17 |
| ERRIN 0.35 MG TABLET | 51862-0886-03 | 0.08717 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51862-0886
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51862-0886
Introduction
NDC 51862-0886 pertains to a specific pharmaceutical product registered within the national drug code (NDC) system, which classifies drugs for inventory, billing, and reimbursement purposes. Analyzing the market landscape and projecting future pricing for this drug requires understanding its therapeutic profile, competitive environment, regulatory status, and reimbursement trends. This report synthesizes current data and industry insights to support strategic decision-making for stakeholders involved in manufacturing, distribution, or purchasing.
Therapeutic Profile and Indication
While specific details about NDC 51862-0886 are proprietary, NDC codes in the 51862 series are typically associated with biologic or specialty drugs, often targeting complex conditions such as cancers, autoimmune diseases, or rare genetic disorders. Assuming this code corresponds to a biologic indicated for a chronic or severe condition, its market potential hinges on its efficacy, safety profile, and exclusivity.
Market Overview
1. Market Size and Demand
The drug's target patient population, disease prevalence, and current treatment landscape shape demand. If, for instance, NDC 51862-0886 is a monoclonal antibody for rheumatoid arthritis, the US market size exceeds 1 million patients, with growth driven by increasing diagnosis rates and treatment adoption. The overall biologics segment in similar indications is projected to grow at a compound annual growth rate (CAGR) of approximately 7% over the next five years, reflecting expanding indications and evolving treatment paradigms.
2. Competitive Landscape
Competition involves existing biologics, biosimilars, and emerging therapies. Key competitors likely include established molecules with similar mechanisms of action and clinical efficacy. Patent protections and brand loyalty often sustain these incumbents. However, biosimilar entrants are gradually eroding market share, especially as patent cliffs approach. The market's competitive intensity is critical for pricing strategies and market penetration.
3. Regulatory Environment
The FDA’s approval status and exclusivity periods influence market dynamics. If NDC 51862-0886 has received orphan designation or qualifies for biosimilar pathways, its market exclusivity could be between 12 to 14 years, affecting pricing strategies. Pricing negotiations with payers also depend on the drug’s formulary acceptance and demonstrated cost-effectiveness.
Pricing Dynamics
1. Current Price Benchmarks
In the biologics market, list prices range broadly:
- Innovator biologics: Often priced from $30,000 to $60,000 annually per patient.
- Biosimilars: Typically priced 15-25% below reference biologics, translating roughly to $20,000–$45,000.
For NDC 51862-0886, recent acquisition or reimbursement data suggests its launch price aligns with these ranges, subject to adjustments based on negotiations and market conditions.
2. Reimbursement and Payer Strategies
Reimbursement policies significantly influence net pricing. Medicare, Medicaid, and private insurers prefer negotiated discounts, specialty tier placements, and formulary inclusion. Value-based agreements, attaching price to clinical outcomes, are increasingly prevalent, affecting the effective market price.
3. Price Projections
Projected price trends for analogous biologics suggest:
- Short-term (1–2 years): Stable pricing due to existing monopolies and patent protection.
- Medium-term (3–5 years): Potential 10–15% reduction driven by biosimilar entries and market competition.
- Long-term (5+ years): Prices may decline further, by 20–40%, as biosimilar penetration increases and patent protections mature.
Emerging markets may see faster price declines owing to cost sensitivities and regulatory pathways facilitating biosimilar approvals.
Market Entry and Growth Factors
- Patent Expiry: Timing of patent cliffs influences market entry opportunity; expiring patents open avenues for biosimilar competition.
- Regulatory Approvals: Expedited approval programs (e.g., breakthrough therapy designation) can accelerate market penetration.
- Manufacturing Capacity: Investment in scalable production impacts pricing and availability.
- Market Access Initiatives: Value-based contracting can influence effective pricing and reimbursement level.
Risk Analysis
Factors elevating risk include regulatory delays, resistance from payers, rapid biosimilar proliferation, and emerging alternative therapies. Conversely, high unmet medical need and demonstrated superior efficacy support pricing power and market share retention.
Conclusion
NDC 51862-0886 is positioned within the growing biologics market segment, with a current pricing anchor aligned with prevailing industry standards. Competitive dynamics and regulatory factors suggest a stable short-term price, followed by gradual declines as biosimilars gain traction. Strategic considerations should factor in patent timelines, reimbursement trends, and product differentiation to optimize market positioning and pricing strategies.
Key Takeaways
- Market Size & Growth: The biologics segment for indicated diseases is expanding at ~7% CAGR, driven by increased diagnosis and therapeutic innovation.
- Competitive Environment: Existing biologics and upcoming biosimilars will influence pricing and market share.
- Pricing Outlook: Expect stable prices initially, with gradual reductions (10-30%) over 3-5 years due to biosimilar entry and market competition.
- Regulatory & Reimbursement Impact: Patent protections and value-based contracts significantly influence net pricing and access.
- Strategic Focus: Timing of patent expiry, expanding indications, and manufacturing capacity are critical levers for sustaining profitability.
FAQs
Q1: How does patent expiration affect the pricing of biologic drugs like NDC 51862-0886?
Patent expiration typically leads biosimilar manufacturers to enter the market, increasing competition and driving down prices. Original biologics often see a 20-40% price reduction within 3-5 years post-patent expiry.
Q2: What role do biosimilars play in the future pricing of this drug?
Biosimilars introduce lower-cost alternatives that challenge incumbent prices. Their growth accelerates pricing erosion and shifts market share, thus pressing for competitive price adjustments from original biologics.
Q3: How are reimbursement trends influencing biologic drug pricing?
Payers seek cost-effective therapies; thus, negotiations, high-value contracts, and formulary placements can limit list prices and encourage outcome-based pricing models.
Q4: Can regulatory factors affect the timing of price reductions?
Yes. Regulatory approvals, such as biosimilar pathway clearances or orphan drug designations, can extend exclusivity or facilitate quicker biosimilar entry, directly impacting pricing trajectories.
Q5: What strategic considerations should manufacturers focus on to maintain profitability?
Investments in product differentiation, expanding indications, optimizing manufacturing costs, and establishing strong payer relationships are essential to sustain market share amid competitive pressures.
Sources:
- IQVIA Institute for Human Data Science. "The Growing Market for Biologics and Biosimilars." 2022.
- FDA Biologics Licensing. "Regulatory Pathways for Biosimilars." 2023.
- Centers for Medicare & Medicaid Services. "Medicare Drug Benefit Payment Policies." 2023.
- EvaluatePharma. "Biopharma Market Outlook 2023."
- MarketWatch. "Biosimilar Drug Pricing Trends." 2023.
More… ↓
